Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Earnings Results, Beats Expectations By $1.09 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $1.09, FiscalAI reports. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the firm posted ($0.44) EPS. The company’s quarterly revenue was up 96.4% on a year-over-year basis.

Here are the key takeaways from Alnylam Pharmaceuticals’ conference call:

• Alnylam reported a landmark commercial quarter with $1.036 billion in combined net product revenues (up 121% YoY), $910 million in TTR revenue, continued GAAP/non‑GAAP profitability, and reiterated 2026 guidance.
• The AMVUTTRA ATTR‑CM launch showed strong momentum — >1,200 new U.S. prescribers, >90% adherence/persistence in real‑world data, durable first‑line access and expanding international reimbursement (including Japan and multiple European markets).
• R&D progress accelerated: vutrisiran and zilebesiran data presented at ACC, a Phase I start for ALN‑2232, and TRITON‑CM enrollment beating expectations with a planned increase to ~1,750 patients while still targeting a 2030 launch if positive.
• Costs and margin pressures rose as non‑GAAP R&D (+39%) and SG&A (+36%) increased to support multiple Phase III programs, while gross margin fell to 80% mainly due to higher AMVUTTRA royalties tied to the annual reset.
• Alnylam reiterated its ambitious Alnylam 2030 goals — two new transformative medicines beyond TTR, RNAi delivery to ≥10 tissues, and ~30% revenue reinvestment in R&D — which are strategically positive but carry execution risk and long timelines.

Alnylam Pharmaceuticals Stock Down 2.9%

Shares of ALNY traded down $8.88 on Friday, reaching $300.61. The company’s stock had a trading volume of 321,239 shares, compared to its average volume of 1,308,125. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The firm has a fifty day moving average of $320.11 and a 200-day moving average of $377.45. The stock has a market capitalization of $40.11 billion, a PE ratio of 175.95 and a beta of 0.39. Alnylam Pharmaceuticals has a twelve month low of $245.96 and a twelve month high of $495.55.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several recent analyst reports. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Truist Financial lowered their price objective on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Jefferies Financial Group reissued a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Weiss Ratings lowered Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, April 6th. Finally, Barclays began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $471.96.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 results significantly beat expectations: EPS $1.99 vs. consensus ~$0.90–1.43 and revenue $1.17B (up ~96% YoY), showing strong topline growth and margin improvement. Earnings Release
• Positive Sentiment: Multiple brokerages reiterate buy/positive views (consensus called a “Moderate Buy”); H.C. Wainwright remains a Buy, supporting analyst confidence in the franchise. Brokerage Consensus H.C. Wainwright
• Positive Sentiment: Wells Fargo nudged its price target slightly higher (to $377) while keeping an “equal weight” rating — a modest vote of confidence but not an outright upgrade. Wells Fargo PT Note
• Neutral Sentiment: FY‑2026 revenue guidance was set to a $5.3B–$5.8B range (consensus ~ $5.6B). The range includes the street number but its breadth may introduce caution around execution. Company Press Release / Slide Deck
• Neutral Sentiment: Detailed Q1 commentary and management remarks are available in the earnings call transcript and analyst write‑ups — useful for assessing product uptake and 2026 drivers but not news by themselves. Earnings Call Transcript Zacks Analysis
• Negative Sentiment: An outside review flagged that ALNY shares carry a “high risk of significant losses” under a Regulation category disclosure — a headline that can drive near‑term selling and increase perceived regulatory/operational risk. Outside Review Warning

Insider Buying and Selling

In related news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Yvonne Greenstreet sold 6,958 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $2,157,536.64. Following the transaction, the chief executive officer owned 85,662 shares in the company, valued at approximately $26,562,072.96. This trade represents a 7.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 38,656 shares of company stock valued at $12,370,696. 0.86% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Daiwa Securities Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares during the period. Golden State Wealth Management LLC boosted its holdings in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the period. Coldstream Capital Management Inc. grew its stake in Alnylam Pharmaceuticals by 2.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 38 shares in the last quarter. Laird Norton Wetherby Wealth Management LLC grew its stake in Alnylam Pharmaceuticals by 3.3% in the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 40 shares in the last quarter. Finally, National Bank of Canada FI raised its holdings in Alnylam Pharmaceuticals by 6.0% during the 3rd quarter. National Bank of Canada FI now owns 957 shares of the biopharmaceutical company’s stock valued at $436,000 after acquiring an additional 54 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.